- $69.32m
- -$115.07m
- $3.90m
- 41
- 57
- 16
- 31
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.32 | ||
| Price to Tang. Book | 0.32 | ||
| Price to Free Cashflow | 1.12 | ||
| Price to Sales | 17.76 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -89.92% | ||
| Return on Equity | -74.55% | ||
| Operating Margin | -5087.9% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4.34 | 223.58 | 13.65 | -32.93 | 3.9 | n/a | n/a | -13.65% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
I-Mab is a global biotech company. The Company is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
Directors
- Jingwu Zhang Zang CHM (65)
- Zheru Zhang PRE (58)
- Joan Shen CEO (59)
- John Long CFO
- Weimin Tang EVP (55)
- Yunhan Lin VPR (43)
- Neil Warma GMG (58)
- Gigi Qi Feng OTH (39)
- Cheng Li OTH (37)
- Ivan Yifei Zhu OTH (52)
- Jielun Zhu OTH (45)
- Wei Fu DRC (39)
- Mengjiao Jiang DRC (41)
- Jie Yu DRC (46)
- Bing Yuan DRC (52)
- Chun Kwok Alan Au IND (48)
- Pamela Klein IND (59)
- Conor Chia-hung Yang IND (58)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- June 30th, 2016
- Public Since
- January 17th, 2020
- No. of Employees
- 220
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 187,452,500
- Address
- Suite 400, 2440 Research Blvd, ROCKVILLE, 20850
- Web
- https://www.i-mabbiopharma.com/
- Phone
- +1 3016702800
- Auditors
- PricewaterhouseCoopers Zhong Tian LLP
Upcoming Events for IMAB
Similar to IMAB
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the I-Mab share price?
As of Today at 20:15 UTC, shares in I-Mab are trading at $0.85. This share price information is delayed by 15 minutes.
How has the I-Mab share price performed this year?
Shares in I-Mab last closed at $0.85 and the price had moved by -53.01% over the past 365 days. In terms of relative price strength the I-Mab share price has underperformed the S&P500 Index by -56.6% over the past year.
What are the analyst and broker recommendations for I-Mab?
The overall consensus recommendation for I-Mab is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the I-Mab dividend yield?
I-Mab does not currently pay a dividend.
Does I-Mab pay a dividend?
I-Mab does not currently pay a dividend.
When does I-Mab next pay dividends?
I-Mab does not currently pay a dividend.
How do I buy I-Mab shares?
To buy shares in I-Mab you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of I-Mab?
As of the previous close price of $0.85, shares in I-Mab had a market capitalisation of $69.32m.
Where are I-Mab shares listed?
Here are the trading details for I-Mab:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: IMAB
What kind of share is I-Mab?
Based on an overall assessment of its quality, value and momentum I-Mab is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a I-Mab share price forecast for 2025?
The analyst consensus target price for shares in I-Mab is $5.00. That is 487.82% above the last closing price of $0.85.
Analysts covering I-Mab currently have a consensus Earnings Per Share (EPS) forecast of -$0.13 for the next financial year.
Find out moreWhat is the trend in the I-Mab share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like I-Mab. Over the past six months, its share price has underperformed the S&P500 Index by -20.53%.
As of the last closing price of $0.85, shares in I-Mab were trading -27.76% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the I-Mab PE Ratio?
The I-Mab PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.85.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of I-Mab?
I-Mab's management team is headed by:
- Jingwu Zhang Zang - CHM
- Zheru Zhang - PRE
- Joan Shen - CEO
- John Long - CFO
- Weimin Tang - EVP
- Yunhan Lin - VPR
- Neil Warma - GMG
- Gigi Qi Feng - OTH
- Cheng Li - OTH
- Ivan Yifei Zhu - OTH
- Jielun Zhu - OTH
- Wei Fu - DRC
- Mengjiao Jiang - DRC
- Jie Yu - DRC
- Bing Yuan - DRC
- Chun Kwok Alan Au - IND
- Pamela Klein - IND
- Conor Chia-hung Yang - IND